Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Search for a Novel Hepatitis B Virus Entry Factor

FY 2016-17

Summary
The hepatitis B virus (HBV) infects the liver and causes the most serious type of viral hepatitis, killing ~750,000 people every year. There remains much unknown about the life cycle of HBV, which greatly hinders the search for a cure. For instance, there is abundant evidence that there remains an unknown receptor (required for viral entry into the cell), since liver-derived cell lines are not highly permissive to HBV entry and addition of the known entry factors to non-liver cells is not enough to confer susceptibility to HBV. The main objective of my research is to identify a novel receptor for HBV that will be a new target for therapeutic drug development, potentially contributing to the elimination of hepatitis B.The receptor will be identified using a complex procedure known as an iterative cyclic packaging rescue screen, which was previously used identify receptors for the hepatitis C virus. Put briefly, DNA isolated from liver tissue and containing all active liver genes will be packaged into lentiviruses. Each lentivirus will contain different genes and be used to infect cells that are not susceptible to HBV, giving the gene they carry to the cell. Cells that receive the gene for the receptor will become susceptible and will be tested using viruses engineered to mimic HBV and carrying an antibiotic resistance gene. HBV-susceptible cells will receive the resistance gene and survive treatment with antibiotics. The genes that survivors have will then be repackaged into new lentiviral particles and used to infect new non-permissive cells, enriching the library for the gene of the receptor. After several rounds of repackaging and testing, the few remaining genes will be isolated from the cells and sequenced to determine the identity of the receptor.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367248
Name
Mora Jonathan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Search for a Novel Hepatitis B Virus Entry Factor
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cdna Library; Co-Receptor; Cyclic Packaging Rescue; Hepatitis B Virus; Host Factors; Lentiviral; Pseudoparticles; Viral Entry
Abstract
The hepatitis B virus (HBV) infects the liver and causes the most serious type of viral hepatitis, killing ~750,000 people every year. There remains much unknown about the life cycle of HBV, which greatly hinders the search for a cure. For instance, there is abundant evidence that there remains an unknown receptor (required for viral entry into the cell), since liver-derived cell lines are not highly permissive to HBV entry and addition of the known entry factors to non-liver cells is not enough to confer susceptibility to HBV. The main objective of my research is to identify a novel receptor for HBV that will be a new target for therapeutic drug development, potentially contributing to the elimination of hepatitis B.The receptor will be identified using a complex procedure known as an iterative cyclic packaging rescue screen, which was previously used identify receptors for the hepatitis C virus. Put briefly, DNA isolated from liver tissue and containing all active liver genes will be packaged into lentiviruses. Each lentivirus will contain different genes and be used to infect cells that are not susceptible to HBV, giving the gene they carry to the cell. Cells that receive the gene for the receptor will become susceptible and will be tested using viruses engineered to mimic HBV and carrying an antibiotic resistance gene. HBV-susceptible cells will receive the resistance gene and survive treatment with antibiotics. The genes that survivors have will then be repackaged into new lentiviral particles and used to infect new non-permissive cells, enriching the library for the gene of the receptor. After several rounds of repackaging and testing, the few remaining genes will be isolated from the cells and sequenced to determine the identity of the receptor.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mora, Jonathan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~